ESR1 and neoplasm: Amir et al. [243] report that in a study on MBC patients, 12.4 % patients with an ERα+ primary tumour had ERα− metastases, whilst 13.2 % of patients with an ERα− primary tumour had ERα+ metastases, indicating a similar level of gain or loss of the oestrogen receptor.